Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093431 | 0.96 | KDM4E (0.43) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6095816 | 0.93 | KDM4E (0.47) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6095735 | 0.93 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6092464 | 0.92 | KDM4E (0.46) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6094372 | 0.91 | ALDH1A1 (0.46) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6093102 | 0.91 | KDM4E (0.41) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6093980 | 0.90 | ALDH1A1 (0.41) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6094238 | 0.86 | ALDH1A1 (0.40) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6093240 | 0.86 | ALDH1A1 (0.42) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6093361 | 0.85 | ALDH1A1 (0.42) | SMN1; SMN2KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | SMN1; SMN2 2431/4885KDM4E 1895/4885ALDH1A1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.